APEX HEALTHCARE BERHAD

(Company No. 473108-T)

SUMMARY OF KEY MATTERS DISCUSSED AT THE TWENTIETH ANNUAL GENERAL MEETING ("AGM") OF THE COMPANY HELD AT BUNGA MELATI ROOM, 7TH FLOOR, RAMADA PLAZA MELAKA, JALAN BENDAHARA, 75100 MELAKA ON THURSDAY, 23 MAY 2019 AT 9.00 A.M.

PRESENT:

DIRECTORS

Dr Kee Kirk Chin

- Chairman and Chief Executive Officer and also a shareholder

Mr Robert Dobson Millner

- Non-Independent Non-Executive Director and also a shareholder

Mr Leong Khai Cheong

- Senior Independent Non-Executive Director and also a shareholder

Ms Heng Su-Ling Mae

- Independent Non-Executive Director

Mr Jackson Chevalier Yap-Kit-Siong

- Independent Non-Executive Director and also a shareholder

Datuk Noharuddin Bin Nordin @ Harun

- Independent Non-Executive Director and also a shareholder

Datuk Phang Ah Tong

- Independent Non-Executive Director and also a shareholder

Mr Kee Kirk Chuen

- Non-Independent Non-Executive Director and also a shareholder

IN ATTENDANCE

Ms Chiew Woon Wui - Financial Controller / Company Secretary

Ms Chan Yoke Peng - Company Secretary

BY INVITATION

Mr Edwin Francis - Messrs Ernst & Young
Mr Yip Zhi Hoe - Messrs Ernst & Young

Mr Nantha Kumar - UOB Kay Hian Securities (M) Sdn. Bhd.
Mr Winston Loh - UOB Kay Hian Securities (M) Sdn. Bhd.
Ms Tan Ping Sin - Boardroom Corporate Services Sdn. Bhd.

(formerly known as Boardroom Corporate Services

(KL) Sdn. Bhd.)

- Summary of Key Matters Discussed at the Twentieth AGM held on 23 May 2019

KEY MATTERS DISCUSSED

A. **PRODUCTION VOLUME**

A question was raised in respect of the growth of production units for tablets and capsules by 80.8% as disclosed on page 13 of the Annual Report and the impact of such increase to the Group's revenue. The Chairman explained that the production of tablets and capsules made up half of the production volume of the manufacturing arm within the Group. The growth in the Group's revenue is not solely dependent on the rise in production units for solid dosage form as the activities of the Group include the wholesaling, sales and marketing and the distribution of pharmaceutical products, in addition to the manufacturing operation. The Chairman further explained that the current plant for solid products has reached maximum capacity and a new plant is needed for sustained business growth.